Which statement is true regarding Entamoeba histolytica?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Diloxanide Furoate is an effective luminal agent for treating Entamoeba histolytica infections. Entamoeba histolytica is a protozoan parasite that causes amebic dysentery and invasive amebiasis in humans. The parasite exists in two forms: the infectious cyst form which survives outside the host, and the trophozoite form which causes disease within the human intestine. When ingested, the cysts survive stomach acid and excyst in the intestine, where trophozoites can invade the intestinal mucosa causing ulceration and bloody diarrhea. In some cases, the parasite can spread hematogenously to extraintestinal sites, most commonly the liver, causing amebic liver abscesses. Diagnosis typically involves microscopic identification of cysts or trophozoites in stool samples or serological tests, as recommended by the 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea 1. Treatment for symptomatic infections usually consists of metronidazole followed by a luminal agent such as paromomycin or diloxanide furoate to eliminate intestinal cysts and prevent relapse. Key points to consider in the management of Entamoeba histolytica infections include:

  • The use of metronidazole as the primary treatment for invasive amebiasis
  • The importance of luminal agents, such as diloxanide furoate, in eliminating intestinal cysts and preventing relapse
  • The need for proper diagnosis, including microscopic identification of cysts or trophozoites in stool samples or serological tests, as outlined in the guidelines 1.

From the FDA Drug Label

Metronidazole possesses direct trichomonacidal and amebacidal activity against T. vaginalis and E. histolytica. The correct answer is A. Diloxanide Furoate is an effective luminal agent is not supported by the text, however, The statement that Metronidazole is effective in treating invasive disease can be inferred from the text, which means option E. Metronidazole is ineffective in treating invasive disease is false. Also, Bactericidal concentrations of metronidazole have also been detected in pus from hepatic abscesses which means option C. It may cause pyogenic liver abscess is plausible, however, the text does not explicitly state that Entamoeba histolytica causes pyogenic liver abscess. The text does not provide information about the location of the liver abscess, so option D. It usually cause abscess in the left lobe of the liver cannot be confirmed. The text does not provide information about Entamoeba histolytica being a common cause of traveler’s diarrhea, so option B. It is a common cause of traveler’s diarrhea cannot be confirmed. Given the provided text, the only statement that can be confirmed as true is that Metronidazole is effective against Entamoeba histolytica, which implies that option E. Metronidazole is ineffective in treating invasive disease is false, however, this is not among the answer options. Among the provided options, only option A. Diloxanide Furoate is an effective luminal agent is related to the treatment of Entamoeba histolytica, and it is the only option that can be considered as true, based on general knowledge, although it is not supported by the provided text. However, according to the provided instructions, the answer should be based on the text, and the text does not support any of the options. Therefore, the answer should be: The FDA drug label does not answer the question.

From the Research

Entamoeba histolytica Statements

  • The following statements are given regarding Entamoeba histolytica:
    • A. Diloxanide Furoate is an effective luminal agent
    • B. It is a common cause of traveler’s diarrhea
    • C. It may cause pyogenic liver abscess
    • D. It usually cause abscess in the left lobe of the liver
    • E. Metronidazole is ineffective in treating invasive disease

Analysis of Statements

  • Statement A: Diloxanide Furoate is an effective luminal agent. This statement is supported by studies 2, 3, 4, 5, which show that diloxanide furoate is used for treating asymptomatic or mildly symptomatic persons who are passing cysts of Entamoeba histolytica and is effective in treating luminal infections.
  • Statement B: It is a common cause of traveler’s diarrhea. There is no evidence in the provided studies to support this statement.
  • Statement C: It may cause pyogenic liver abscess. While Entamoeba histolytica can cause liver abscess, the provided studies 3, 4 do not specify that it is pyogenic.
  • Statement D: It usually cause abscess in the left lobe of the liver. The provided studies do not specify the location of the liver abscess.
  • Statement E: Metronidazole is ineffective in treating invasive disease. This statement is not supported by the studies 3, 4, 5, which show that metronidazole is effective in treating invasive amebiasis, including amebic liver abscess.

Correct Statement

  • Based on the analysis, statement A is the correct statement, as diloxanide furoate is an effective luminal agent for treating Entamoeba histolytica infections, as supported by studies 2, 3, 4, 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Diloxanide furoate for treating asymptomatic Entamoeba histolytica cyst passers: 14 years' experience in the United States.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1992

Research

Therapy of entamebiasis.

Journal of chemotherapy (Florence, Italy), 1989

Research

[Therapy for malaria and amoebiasis].

Immunitat und Infektion, 1994

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.